When a scan shows pancreatic cancer has already spread, the options are limited and time feels short. A small early trial at Cedars-Sinai suggests that adding a simple amino acid called L-glutamine to standard chemotherapy may help some patients. The researchers stress that it’s far too early to call it a breakthrough.
Key Takeaways
- In a 16-patient trial, tumors shrank in 15 people (94%) who took high-dose oral L-glutamine alongside standard chemotherapy for advanced pancreatic cancer. The study was published in Nature Cancer on August 31, 2026.
- Two patients’ tumors disappeared on scans, and median survival reached 22 months. Standard chemotherapy alone has historically produced roughly 8 to 13 months.
- The trial had no comparison group, so it can’t show that glutamine caused the better results. The authors say their findings don’t prove the combination beats chemo alone.
- Researchers think glutamine may make cancer cells more sensitive to chemotherapy and support gut health in patients who struggle to absorb nutrients.
- Patients should not start glutamine on their own. The trial used a high, medically supervised dose, and larger randomized studies are still needed.
What the trial found
The phase 1 trial, called GlutaPanc, enrolled people with advanced pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer, who had not yet started treatment. Fifteen had cancer that had spread to other organs. All received the standard first-line chemotherapy combination of gemcitabine and nab-paclitaxel, plus oral L-glutamine twice daily at doses of up to 30 grams a day.
Results among the 16 evaluable patients:
- 2 (12.5%) had a complete response, meaning their tumors were no longer visible on imaging.
- 5 (31%) had a partial response, meaning their tumors shrank substantially.
- 8 (50%) had stable disease.
- 1 saw the cancer grow.
Median progression-free survival, how long patients lived before the cancer worsened, was 8.5 months. Median overall survival was 22 months, and about 40% of patients were still alive at two years.
That compares favorably with past results. In the major trial that established gemcitabine plus nab-paclitaxel as a standard treatment, median survival was about 8.5 months. But comparing one small trial with an older, much